Get the Stockscreener App
0.4945
0.94%
+0.0046
After Hours:
.4933
-0.0012
-0.24%
Salarius Pharmaceuticals Inc stock is currently priced at $0.4945, with a 24-hour trading volume of 40,974.
It has seen a +0.94% increased in the last 24 hours and a -3.14% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4809 pivot point. If it approaches the $0.5038 resistance level, significant changes may occur.
Previous Close:
$0.4899
Open:
$0.47
24h Volume:
40,974
Market Cap:
$2.36M
Revenue:
$4.70M
Net Income/Loss:
$-12.54M
P/E Ratio:
-0.0386
EPS:
-12.82
Net Cash Flow:
$-12.85M
1W Performance:
-1.10%
1M Performance:
-3.14%
6M Performance:
-28.33%
1Y Performance:
-65.42%
1D Range:
$0.461
$0.50
52W Range:
$0.43
$1.8694
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
832 834 6992
Address
2450 Holcombe Boulevard, Suite X, Houston
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Salarius: Q1 Earnings Snapshot | Region | jacksonvilleprogress.com - Jacksonville Daily Progress
Jacksonville Daily Progress
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World
Defense World
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Benzinga
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday - Markets Insider
Markets Insider
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
Benzinga
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Salarius Pharmaceuticals Inc (SLRX) Revenue 2024
SLRX reported a revenue (TTM) of $4.70 million for the quarter ending June 30, 2021.
Salarius Pharmaceuticals Inc (SLRX) Net Income 2024
SLRX net income (TTM) was -$12.54 million for the quarter ending December 31, 2023, a +60.32% increase year-over-year.
Salarius Pharmaceuticals Inc (SLRX) Cash Flow 2024
SLRX recorded a free cash flow (TTM) of -$12.85 million for the quarter ending December 31, 2023, a +32.73% increase year-over-year.
Salarius Pharmaceuticals Inc (SLRX) Earnings per Share 2024
SLRX earnings per share (TTM) was -$4.31 for the quarter ending December 31, 2023, a +70.60% growth year-over-year.
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
0.77%
1.20%
Cap:
|
Volume (24h):